Regulator concerned about potential abuse of Opana ER
FDA makes unprecedented move, asks Endo to pull painkiller from market
Risks of Endo painkiller outweigh benefits, say FDA advisers
Data could be used to fend off generic competition.
FDA delays decision on abuse deterrence data on Endo painkiller